FDA approves first treatment for rare skin disorder

The FDA approved Oct. 8 the first treatment for a rare skin disease that causes pain when exposed to sunlight.

Australian drugmaker Clinuvel received orphan status for its treatment, Scenesse, which is an implant that is inserted under the skin.

The treatment is designed for adults with erythropoietic protoporphyria. For patients with the rare disorder, light exposure can be extremely painful and cause skin redness and thickening.

Side effects of the implant include implant site reactions, nausea, pain and fatigue.

Read the full news release here.

More articles on pharmacy:
Telemedicine startup to open first brick-and-mortar pharmacy
Top 10 pharmacy stories in September
Novant Health to open health clinics inside Walgreens

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months